Ernexa Therapeutics (ERNAW) Convertible Debt (2023 - 2024)
Ernexa Therapeutics' (ERNAW) quarterly Convertible Debt came in at $32.0 million in Q3 2024, up 828.07% YoY from $3.5 million in Q4 2023, and up 260.17% on a QoQ basis from $8.9 million in Q2 2024.
Powered by 
Analysis
Ernexa Therapeutics (ERNAW) Convertible Debt (2023 - 2024) Analysis & Trends
Ernexa Therapeutics (ERNAW) has 2 years of Convertible Debt data on file, last reported at $32.0 million in Q3 2024.
- Quarterly Convertible Debt rose 828.07% year-over-year to $32.0 million in Q3 2024, while the trailing twelve-month figure through Sep 2024 was $32.0 million (up 828.07% YoY) and the FY2023 annual result came in at $6.8 million, changed N/A from the prior year.
- Convertible Debt improved to $32.0 million in Q3 2024, from $8.9 million in the prior quarter.
- In the past five years, Convertible Debt ranged from a high of $32.0 million in Q3 2024 to a low of $3.5 million in Q3 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Ernexa Therapeutics | 67,312.70 | 67,312.70 | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2024 | 32.04 Mn |
| Jun 30, 2024 | 8.90 Mn |
| Mar 31, 2024 | 8.01 Mn |
| Dec 31, 2023 | 6.77 Mn |
| Sep 30, 2023 | 3.45 Mn |